Marek Straka
🟢What will be the main driver for Novo Nordisk’s growth in 2026? 🚀 Wegovy Pill (The shift from injections to tablets) 💊 Ozempic Dominance (Steady cash flow from diabetes care) 🩸 Beyond Weight Loss (New heart and kidney health benefits) ❤️ CagriSema (The next-gen combo treatment) 🧬
Not investment advice. The author may have financial interests in the mentioned instruments.
Wegovy Pill 💊
100.00%
Ozempic Dominance 🩸
100.00%
Beyond Weight Loss ❤️
100.00%
CagriSema 🧬
100.00%
null
.